Tyra Biosciences

Tyra Biosciences

Yahoo Finance • last month

Raymond James Updates Healthcare Top Picks for October

Investing.com -- Raymond James has updated its Healthcare Top Picks list for October, adding three new stocks while removing others from the monthly selection. The firm added Xencor, Calyxt, and UnitedHealth Group to replace Relay Therapeu... Full story

Yahoo Finance • 2 months ago

Tyra Plummets To 10-Month Low On Mixed Cancer Test; Why Analysts Are Upbeat

Tyra stock plummeted to a 10-month low Wednesday on mixed test results for its experimental bladder cancer treatment. Continue Reading... Full story

Yahoo Finance • 2 months ago

Tyra Bio rises on upcoming mid-stage trial readout for bladder cancer drug

[Cancer cells on human tissue. 3D illustration.] anusorn nakdee Tyra Biosciences (TYRA [https://seekingalpha.com/symbol/TYRA]) added more than 13% on Thursday, marking its best intraday rally since January, after scheduling a conference c... Full story

Yahoo Finance • 3 months ago

At a glance: stocks gapping down premarket

[Wall Street sign, New York City, USA] mbbirdy/E+ via Getty Images Here's a quick look at the stocks that are seeing gap-down moves before the bell on Wednesday. U.S. stock index futures rose on Wednesday as Wall Street looked to continu... Full story

Yahoo Finance • 4 months ago

Is Tyra Biosciences, Inc. (TYRA) Stock a Biotech Opportunity Ahead of Key SURF302 Trial Data?

We recently compiled a list of the 10 Most Promising Cancer Stocks According to Wall Street Analysts. Tyra Biosciences, Inc. (NASDAQ:TYRA) is one of the most promising stocks on our list. TheFly reported on June 17 that Oppenheimer initia... Full story

Yahoo Finance • 6 months ago

Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares

On May 15, 2026, HighVista Strategies disclosed a purchase of 96,218 shares of Tyra Biosciences(NASDAQ:TYRA), estimated at $3.11 million based on quarterly average pricing. What happened According to its SEC filing dated May 15, 2026, Hi... Full story

Yahoo Finance • 8 months ago

Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026

On February 17, 2026, Boone Capital Management sold out its entire Cogent Biosciences(NASDAQ:COGT) stake, liquidating 945,042 shares previously worth $13.57 million. What happened According to an SEC filing dated February 17, 2026, Boone... Full story

Yahoo Finance • 8 months ago

This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position

On February 17, 2026, Boone Capital Management disclosed a new position in Tyra Biosciences(NASDAQ:TYRA), acquiring 398,482 shares worth $10.48 million at quarter’s end. What happened According to a Securities and Exchange Commission (SE... Full story

Yahoo Finance • 8 months ago

Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit

Key Points 5AM Venture Management sold 365,053 shares of Dianthus Therapeutics in the fourth quarter. The quarter-end position value decreased by $14.36 million as a result of the sale, which marked a full exit from Dianthus. The position... Full story

Yahoo Finance • 9 months ago

Tyra Biosciences price target raised to $53 from $37 at Wedbush

Wedbush analyst Robert Driscoll raised the firm’s price target on Tyra Biosciences (TYRA) to $53 from $37 and keeps an Outperform rating on the shares. The firm notes BridgeBio (BBIO) announced positive topline Phase 3 data for infigratini... Full story

Yahoo Finance • last year

H.C. Wainwright reiterates Buy rating on Tyra Biosciences stock at $30

Investing.com - H.C. Wainwright has reiterated its Buy rating and $30.00 price target on Tyra Biosciences (NASDAQ:TYRA), representing over 200% upside from the current price of $9.57, following the company’s announcement that the first p... Full story

Yahoo Finance • last year

Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)

-TYRA-300 is the only orally administered investigational agent in clinical development for IR NMIBC- -Initial 3-month complete response (CR) data expected to be reported in 1H 2026- CARLSBAD, Calif., June 30, 2025 /PRNewswire/ -- Tyra B... Full story

Yahoo Finance • last year

Tyra Biosciences begins dosing in Phase 2 trial for TYRA-300 in bladder cancer

Tyra Biosciences , Inc. (NASDAQ:TYRA), a clinical-stage biotech company with a market capitalization of $484 million, announced Monday that it has dosed the first patient in its SURF302 Phase 2 clinical study of TYRA-300 for the treatment... Full story

Yahoo Finance • 3 years ago

16 Most Promising Long-Term Stocks According to Analysts

In this piece, we will take a look at the 16 most promising long-term stocks according to analysts. If you want to skip our overview of long term investing, then you can take a look at 5 Most Promising Long-Term Stocks According to Analyst... Full story